Results 21 to 30 of about 2,401 (204)

Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment

Consortium Psychiatricum, 2020
Background. Cariprazine is a new piperazine derivative atypical antipsychotic, like aripiprazole and brexpiprazole. It has been approved for treating schizophrenia in many countries and has recently been included on the List of Essential Medicines in ...
Aleksandr M. Reznik, Aleksandr L. Arbuzov, Sergey P. Murin, Aleksey V. Pavlichenko   +3 more
doaj   +1 more source

Hypersexuality during treatment with cariprazine in a patient with schizophrenia? A case report

BMC Psychiatry, 2023
Background Cariprazine is a third-generation antipsychotic with a unique mechanism of action. It functions as a partial agonist with high affinity for dopamine D2 and D3 and serotonin 5-HT1A receptors, an antagonist for 5-HT2A (moderate affinity) and 5 ...
Polona Rus Prelog, Anja Kokalj Palandacic   +1 more
doaj   +1 more source

Evaluation of the Effect of Cariprazine on Memory and Cognition in Experimental Rodent Models [PDF]

, 2022
The main symptoms of schizophrenia are categorized as positive, negative, and cognitive. Cognitive impairments do not generally respond to antipsychotics.
Vilmosh, Natalia Borisova, Ilin Kostadinov Kandilarov, Hristina Ivanova Zlatanova, Maria Todorova Georgieva-Kotetarova, Georgieva-Kotetarova, Maria Todorova, Kandilarov, Ilin Kostadinov, Natalia Borisova Vilmosh, Zlatanova, Hristina Ivanova   +7 more
core   +1 more source

Cariprazine: a review in schizophrenia [PDF]

, 2018
Compliance with Ethical StandardsFunding The preparation of this review was not supported by any external funding.Conflicts of interest Karly Garnock-Jones is a salaried employee of Adis/Springer, is responsible for the article content and declares no ...
Karly Garnock-Jones (4985351)
core   +1 more source

Review of cariprazine in management of psychiatric illness [PDF]

, 2017
Schizophrenia and bipolar disorder are severe and debilitating psychiatric disorders. Despite the availability of numerous antipsychotic drugs, many patients still experience poor outcomes and treatment-limiting adverse side effects.
Kristen N. Gardner, Christopher Thomas, Rebecca H. Campbell, Michael Diduch   +3 more
core   +1 more source

Therapeutic Appropriateness of Cariprazine in the Management of Schizophrenia: Experts’ Opinion using a Delphi Approach [PDF]

, 2023
Background: Schizophrenia is a psychiatric disorder whose therapeutic objectives are aimed at reducing symptoms and improving patient's quality of life. First- and second-generation antipsychotics present numerous side effects. Recently introduced in the
Bellomo, Antonello, Domenico De Berardis, Massimo Di Giannantonio, Virginio Salvi, Maria Conca, Andreas Pietro, Berardis, Domenico De, Bernardo Dell’Osso, Salvi, Virginio, Alberto Siracusano, Antonello Bellomo, Andreas Pietro Maria Conca, Carmelo Zaffora, Dell'Osso, Bernardo, Giannantonio, Massimo Di, Zaffora, Carmelo, Siracusano, Alberto   +15 more
core   +1 more source

Case series: Cariprazine in early-onset schizophrenia

Frontiers in Psychiatry, 2023
IntroductionNegative symptoms are part of the clinical manifestations of schizophrenia and their presence is associated with a poorer prognosis, significantly limited vocational opportunities, impaired quality of life and social functioning.
Elena Ivanova, Elena Ivanova, Desislava Maslinkova, Desislava Maslinkova, Nadia Polnareva, Vihra Milanova   +5 more
doaj   +1 more source

Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study)

Frontiers in Psychiatry, 2022
BackgroundBecause of limited efficacy of antipsychotics against negative symptoms in schizophrenia new drugs with wider spectrums of clinical efficacy are very desirable.
Stanislav V. Ivanov, Stanislav V. Ivanov, Anatoly B. Smulevich, Anatoly B. Smulevich, Evgeniya I. Voronova, Evgeniya I. Voronova, Kausar K. Yakhin, Tangyul Z. Beybalaeva, Alena A. Katok   +8 more
doaj   +1 more source

Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania

Clinical and Translational Science, 2020
Population pharmacokinetic/pharmacodynamic modeling (via NONMEM) was used to describe longitudinal exposure‐response relationships for total cariprazine (sum of cariprazine and its major active metabolites) in 2,558 patients with schizophrenia or bipolar
Antonia Periclou, Susan Willavize, David Jaworowicz, Julie Passarell, Timothy Carrothers, Parviz Ghahramani, Suresh Durgam, Willie Earley, Margit Kapás, Tatiana Khariton   +9 more
doaj   +1 more source

The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia

European Psychiatry, 2021
Introduction Motivation deficit is a significant aspect of lack of improvement in patients with schizophrenia especially with predominant negative symptoms (PNS).
I. Laszlovszky, Z.B. Dombi, Á. Balogh, Á. Barabássy, G. Vass, B. Szatmári, G. Németh   +6 more
doaj   +1 more source